Genetic mutations in early-onset Parkinson's disease Mexican patients: molecular testing implications

Nancy Monroy-Jaramillo1, Jorge Luis Guerrero-Camacho, Mayela Rodríguez-Violante

  • 1Neurogenetics Department, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Mexico City, Mexico; PhD Candidate in Biological and Health Sciences, Universidad Autónoma Metropolitana, Mexico City, Mexico.

Insights

Genetic mutations in PARK2 and PINK1 are common in Mexican Mestizo patients with early-onset Parkinson's disease, including novel findings and digenic inheritance. These results impact genetic counseling for Parkinson's disease.

Area of Science:

  • Genetics
  • Neuroscience
  • Molecular Biology

Background:

  • Autosomal recessive early-onset Parkinson's disease is linked to mutations in PARK2, PINK1, and DJ-1.
  • Understanding the prevalence of these mutations in diverse populations is crucial for diagnosis and treatment.

Purpose of the Study:

  • To determine the prevalence of sequence and structural mutations in PARK2, PINK1, and DJ-1 in Mexican Mestizo Parkinson's disease patients.
  • To identify novel mutations and assess the role of digenic inheritance and heterozygous mutations.

Main Methods:

  • Analysis of complete gene sequences (PARK2, PINK1, DJ-1) using homo/heteroduplex DNA formation and direct sequencing.
  • Exon dosage determination via multiplex ligation-dependent probe amplification and real-time PCR.
  • Screening for common LRRK2 mutations in 127 patients and 120 controls.

Main Results:

  • Mutations were found in 16 unrelated patients: 10 in PARK2 and 6 in PINK1; no mutations in DJ-1.
  • Identified novel mutations in PARK2 and PINK1, including the first reported PINK1 duplication.
  • High prevalence of heterozygous PARK2 mutations (12.3%) and novel PINK1 mutations suggest a pathogenic role for single heterozygous mutations.

Conclusions:

  • PARK2 and PINK1 mutations are significant contributors to early-onset Parkinson's disease in Mexican Mestizo patients.
  • Digenic inheritance (e.g., PARK2-PINK1, PARK2-LRRK2) occurs and necessitates multi-gene analysis.
  • Findings support a pathogenic role for heterozygous mutations and inform genetic counseling strategies.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
7.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121